PDS Biotechnology (NASDAQ:PDSB) Stock Price Down 1.2% – Here’s What Happened

PDS Biotechnology Corporation (NASDAQ:PDSB)’s share price traded down 1.2% during mid-day trading on Monday . The stock traded as low as $0.6012 and last traded at $0.6401. 495,825 shares changed hands during trading, a decline of 23% from the average session volume of 646,099 shares. The stock had previously closed at $0.6480.

Wall Street Analyst Weigh In

PDSB has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. B. Riley Financial lowered their price target on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, November 25th. Finally, HC Wainwright boosted their price objective on PDS Biotechnology from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Stock Performance

The stock’s 50-day simple moving average is $0.84 and its 200-day simple moving average is $0.95. The stock has a market cap of $31.35 million, a price-to-earnings ratio of -0.78 and a beta of 1.21. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds have recently added to or reduced their stakes in PDSB. Tempus Wealth Planning LLC raised its holdings in shares of PDS Biotechnology by 29.3% during the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after buying an additional 14,000 shares in the last quarter. Virtu Financial LLC acquired a new position in PDS Biotechnology during the fourth quarter worth about $25,000. Geode Capital Management LLC raised its stake in PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after acquiring an additional 38,399 shares in the last quarter. Watts Gwilliam & Co. LLC bought a new position in shares of PDS Biotechnology in the second quarter worth about $73,000. Finally, Marshall Wace LLP acquired a new stake in shares of PDS Biotechnology in the 2nd quarter valued at approximately $91,000. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.